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and Clinique Pasteur Toulouse, FranceBackground Limited data suggest that transcatheter (TAVR) as compared with surgical aortic valve replacement (SAVR)
may be more effective in female than male patients. To date, most evidence is derived from subgroup analyses of large trials,
and a dedicated randomized trial evaluating whether there is a difference in outcomes between these interventions in women is
warranted. The RHEIA trial will compare the safety and efficacy of TAVR with SAVR in women with severe symptomatic aortic
stenosis requiring aortic valve intervention, irrespective of surgical risk.
Methods/Design The RHEIA trial is a prospective, randomized, controlled study that will enroll up to 440 patients
across 35 sites in Europe. Women with severe symptomatic aortic stenosis, with any but prohibitive surgical risk status, will be
randomized 1:1 to undergo aortic valve intervention with either transfemoral TAVR with the SAPIEN 3 or SAPIEN 3 Ultra
device or SAVR and followed up for 1 year. The objective is to determine whether TAVR is non-inferior to SAVR in this patient
population and, if this is fulfilled whether TAVR is actually superior to SAVR. The primary safety/efficacy endpoint is a
composite of all-cause mortality, all stroke, and re-hospitalization (for valve or procedure-related symptoms or worsening
congestive heart failure) at 1 year post-procedure. Other outcomes (assessed at 30 days and/or 1 year) include all-cause
mortality; bleeding, vascular, cardiac, cerebrovascular and renal complications; aortic valve prosthesis and left ventricular
function; cognitive function, health status, and quality of life.
Discussion The RHEIA study has been designed to evaluate the safety and efficacy of TAVR compared with SAVR
specifically in women with severe symptomatic aortic stenosis, irrespective of the level of surgical risk. The results will be the first
to provide specific randomized evidence to guide treatment selection in female patients with severe symptomatic aortic
stenosis.
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Aortic stenosis affects approximately 12% of elderly
people in western countries and, given the aging
population, the prevalence is expected to increase in
coming years, especially in women because of their
increased life expectancy.1 Interventional treatment
options for patients with symptomatic severe aortic
stenosis include surgical aortic valve replacement (SAVR),
transcatheter aortic valve replacement (TAVR) and
balloon aortic valvuloplasty.2 SAVR has been generally
favored in patients at low surgical risk, while TAVR is
favored in patients at intermediate, high or prohibitive
surgical risk.2 However, there is an increasing trend, to
perform TAVR in lower risk patients as evidence from
randomized clinical trials up to 1-year follow-up indicates
that TAVR is at least non-inferior to SAVR in patients at
low surgical risk.3,4
There appears to be a gender difference in outcomes after
aortic valve interventions. Women have an increased risk of
adverse outcomes after SAVR.5-8 In contrast, there is
evidence of improved long-term survival in women versus
men after TAVR, although women experience more
bleeding or vascular complications.9-13 In the WIN TAVI
registry (the first all-female TAVR registry with collection of
female sex-specific baseline parameters), a total of 1019
intermediate to high-risk women with severe symptomatic
aortic stenosiswere enrolled. At 30-day and 1-year follow-up,
the VARC-2 composite safety endpoint was 14.0% and
16.5%, respectively with a low incidence of early mortality
and stroke. Prior revascularization and EuroSCORE I were
independent predictors of the VARC-2 efficacy endpoint,
whereas EuroSCORE I, baseline atrial fibrillation, and prior
percutaneous coronary intervention were independent
predictors of death or stroke at the 1-year follow-up.14,15
Furthermore, data from meta-analyses of randomized
trials comparing TAVR with SAVR for the treatment of
symptomatic severe aortic stenosis reported TAVR to be
associated with a survival benefit compared with SAVR in
women but not men.16,17 One of these reports found a 13%
relative risk reduction in 2-year all-cause mortality in favor of
TAVR compared with SAVR in the overall analysis popula-
tion (hazard ratio 0.87, 95% confidence interval 0.76-0.99,
P = .038); noteworthy, the benefit was driven by a
significant reduction inmortality amongwomenundergoing
TAVR (HR 0.68, 95% CI 0.50-0.91, P = .010), with no
difference evident in men (HR 0.99, 95% CI 0.77-1.28, P =
.952). 16 Another meta-analysis found that TAVR
was associated with reduced mortality compared
with SAVR in women at both 1 (odds ratio 0.68, 95% CI
0.50-0.94) and 2 years follow-up (OR 0.74, 95%CI 0.58-0.95),
whereas there was no difference among men at either time
point (OR 1.09, 95% CI 0.86-1.39 and OR 1.05, 95% CI 0.85-
1.30, respectively).17 The difference in treatment effect
between the sexes was significant at both 1 (P = .02) and 2
years (P = .04). Additional analysis of the data for women
revealed lower rates of peri-procedural mortality, bleeding,acute kidney injury, and severe prosthesis-patient mismatch,
and better left ventricular function recovery following TAVR
compared with SAVR.17 Notably, peri-procedural mortality
and major bleeding were 54% and 57% lower, respectively,
after TAVR compared with SAVR.
In light of the available evidence suggesting a favorable
risk reduction with TAVR compared with SAVR in
women, it is appropriate to conduct a prospective
dedicated trial to determine the extent of a difference
in outcomes between these interventions in women with
severe symptomatic aortic stenosis. To this end, the
RHEIA trial will compare the safety and efficacy of TAVR
with SAVR in women with severe symptomatic aortic
stenosis requiring aortic valve replacement, irrespective
of their level of surgical risk.
Methods/design
The RHEIA trial is a prospective, randomized, con-
trolled study that will enroll up to 440 patients across 35
sites in Europe (Austria, Finland, France, Germany,
Ireland, Italy, the Netherlands, Sweden, Switzerland,
United Kingdom) (Figure 1). Women with severe
symptomatic aortic stenosis with indication for aortic
valve intervention will be randomly assigned to undergo
aortic valve intervention by either TAVR or SAVR and
followed up for 1 year post-procedure. The primary
objective is to determine whether TAVR is non-inferior to
SAVR in this patient population and, if this is fulfilled
whether TAVR is superior to SAVR.
Approval will be obtained from the responsible ethics
committees/institutional review boards prior to study
commencement. All patients will provide written in-
formed consent before enrolment, and the study will be
conducted in accordance with medical device-specific
Good Clinical Practice and the principles of the
Declaration of Helsinki. The trial is registered with
clinicaltrials.gov under the number NCT04160130.
Patients
Women aged ≥18 years with symptomatic severe
aortic stenosis, who are operable and with any surgical
risk status, and who meet all the inclusion criteria and
none of the exclusion criteria presented in Table I, will be
eligible for participation in the study. Potential candidates
will be screened by site investigators for operative risk
and eligibility criteria, after which each case will be
reviewed by a Case Review Board to confirm their
suitability for enrolment.
Procedures and data collection
Patients whose eligibility is confirmed will be random-
ized 1:1 to undergo treatment by either transfemoral
TAVR or conventional SAVR. Randomization will be
performed centrally by an electronic system. Valve
implant procedures will occur within 14 days of
Figure 1
Trial Design.
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Volume 228randomization. TAVR will be performed by transfemoral
access using the SAPIEN 3 (model 9600TFX) or SAPIEN 3
Ultra (model 9750TFX) transcatheter heart valve and
associated delivery systems, in accordance with the
relevant Instructions for Use for device sizing, prepara-
tion and recommended implant procedure. SAVR will be
performed using a commercially available surgical valve
and associated components, in accordance with the
standard of care at the institution. The protocol also
includes new generation sutureless or rapid deployment
valve and does not exclude surgical annulus enlargement.
Prior to the start of the study, investigators will undergo
guided review of the Instructions for Use of the devices,
to ensure correct device usage. Study sites will be
provided with uniform guidance on anticoagulation/
antithrombotic regimens.
All patients who receive a SAPIEN 3 or SAPIEN 3 Ultra
transcatheter heart valve or undergo SAVR will continue
in the study throughout 1-year post-procedure (including
patients who are randomized to TAVR but are subse-
quently converted to SAVR).
Data will be collected prospectively according to the
schedule presented in Table II. Assessments will include
medical history, physical examinations, electrocardio-
grams, echocardiograms, laboratory tests, neurological
assessments, medications, adverse events, and quality-of-
life questionnaires. Echocardiograms will be performed
according to a standardized protocol and images will be
analyzed by a central echocardiography core laboratory.
Data will be entered onto electronic case report forms bystudy site and central laboratory personnel, and checked
for completeness and accuracy by automated systems and
by on-site monitoring.
An independent clinical events committee, which will
include cardiologists and cardiothoracic surgeons expe-
rienced in the field of aortic stenosis, will adjudicate
endpoint events (unblinded) and assess serious adverse
events and device/procedure relatedness. An indepen-
dent Data Safety Monitoring Board, which will include at
least one cardiothoracic surgeon experienced in aortic
stenosis, will monitor all adverse events.
Outcome measures
The primary endpoint is a composite clinical safety/
efficacy endpoint, comprising all-cause mortality, stroke
(disabling and non-disabling), and re-hospitalization (for
valve or procedure-related symptoms or worsening
congestive heart failure) at 1 year post-procedure.
Definitions are as to VARC-2.
Additional combined safety/efficacy endpoints include:
death or stroke (disabling and non-disabling) at 30 days
and 1 year; death or disabling stroke at 30 days and 1 year;
and death or disabling stroke or rehospitalization at
1 year.
Single safety/efficacy endpoints that will assessed at
both 30 days and 1 year include mortality (all cause and
cardiovascular); stroke (disabling and non-disabling);
rehospitalization (valve-related or procedure-related or
worsening congestive heart failure); new-onset atrial
fibrillation; major vascular complications; bleeding
Table I. Eligibility criteria for the RHEIA trial
Inclusion criteria
● Female patients with severe symptomatic aortic stenosis requiring
aortic valve replacement
● Severe aortic stenosis as follows:
○ High gradient severe AS (Class I Indication for AVR): peak aortic jet
velocity ≥ 4.0m/sormeangradient≥40mmHgwithAVA≤1.0 cm2or
AVA index ≤0.6 cm2/m2, OR
○ Low gradient severe AS (Class I/IIa indication of AVR): peak aortic
jet velocityb 4.0m/s andmeangradientb40mmHgandAVA≤1.0 cm2
andAVA index ≤0.6 cm2/m2, with confirmation of severe AS by amean
gradient ≥40 mmHg on dobutamine stress echocardiography and/or
aortic valve calcium score ≥ 1200 AU on non-contrast CT
● NYHA Functional Class ≥ II, OR exercise test that demonstrates a limited
exercise capacity, abnormal BP response, or arrhythmia
● Age ≥ 18 years
● Provided written informed consent
Exclusion criteria
● Patient is not a candidate for both surgical and transcatheter aortic valve
intervention
● Native aortic annulus size unsuitable for sizes 20, 23, 26, or 29 mm
transcatheter heart valve based on 3D imaging analysis
● Iliofemoral vessel characteristics precluding safe placement of the
introducer sheath
● Evidence of an acutemyocardial infarction≤30 days before randomization
● Aortic valve is unicuspid, bicuspid, or is non-calcified
● Severe aortic regurgitation
● Any concomitant valve disease that requires an intervention
● Pre-existing mechanical or bioprosthetic valve in any position
● Complex coronary artery disease
● Unprotected left main coronary artery stenosis
● Syntax score N32 (in the absence of prior revascularization)
● Heart Teamassessment that optimal revascularization cannot be performed.
● Symptomatic carotid or vertebral artery disease or successful treatment of
carotid stenosis within 30 days of randomization
● Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis,
coagulopathy, or hypercoagulable states
● Hemodynamic or respiratory instability requiring inotropic support,
mechanical ventilation or mechanical heart assistance within 30
days of randomization
● Hypertrophic cardiomyopathy with obstruction
● Ventricular dysfunction with left ventricular ejection fraction b30%
● Cardiac imaging evidence of intra-cardiac mass, thrombus or vegetation
● Inability to tolerate, or condition precluding, anti-thrombotic/anticoagulation
therapy during or after the valve implant procedure
● Stroke or transient ischemic attack within 90 days of randomization
● Renal insufficiency (eGFR b30 ml/min per the Cockcroft-Gault formula)
and/or renal replacement therapy
● Active bacterial endocarditis within 180 days of randomization
● Severe lung disease or currently on home oxygen
● Severepulmonaryhypertension (PAsystolic pressure≥2/3 systemicpressure)
● History of cirrhosis or any active liver disease
● Significant abdominal or thoracic aortic disease that would preclude safe
passage of the delivery system or cannulation and aortotomy for surgical AVR
● Hostile chest or conditions or complications from prior surgery that
preclude safe reoperation
● Patient refuses blood products
● Body mass index N50 kg/m2
● Estimated life expectancy b24 months
● Absolute contraindications or allergy to iodinated contrast
● Immobility that would prevent completion of study procedures
● Currently participating in an investigational drug or another device study
● Pregnancy or lactation
AS, aortic stenosis; AVA, aortic valve area; AVR, aortic valve replacement; CT, computed
tomography; NYHA, New York heart Association; RHEIA, Randomized researcH in womEn
all comers wIth Aortic stenosis.
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myocardial infarction; new permanent pacemaker
implantation resulting from new or worsened conduction
disturbances; New York Heart Association class;
hemodynamic valve performance evaluation by echocar-
diography for aortic valve stenosis and aortic valve
regurgitation (paravalvular and central); cognitive
function (mini-Mental State Examination, National Insti-
tutes of Health Stroke Scale,modified Ranking Scale); frailty
assessment; health status as evaluated by quality-of-life
questionnaires (Kansas City Cardiomyopathy Question-
naire, SF-12 = 12-item Short Form survey). Other safety/
efficacy endpoints include: length of index hospitalization;
moderate and/or severe prosthesis-patient mismatch at 30
days; acute kidney injury stage II/III (AKIN classification) at
30 days; and renal replacement therapy at 1 year.
Sample size
Event rate estimates for the primary endpoint were
based on data from the PARTNER 3 study.18 The sample
size estimation assumes an event rate for the composite
primary endpoint of 16% in the SAVR arm and 8% in the
TAVR arm. Using a one-sided alpha = 0.05 and a specified
non-inferiority margin of 6.0%, a sample size of 132
patients with 1-year data would provide 80% power to
fulfill non-inferiority (Figure 2). A sample size of 402
patients would provide 70% power (two-sided alpha
0.05) or 80% for a one-sided slpha of 0.05) to fulfill
superiority. Because the feasibility assumptions are
uncertain in an all-comer (i.e. including low to interme-
diate surgical risk) population and patients dropping out,
an actual sample size of 440 has been chosen.
Statistical analysis
The primary population for endpoint analysis will be
the As Treated population (patients in whom the index
procedure is begun, whether or not the procedure is
completed). The As-Treated population was chosen as
patients dying before the intervention, with protocol
violations and withdrawing their consent would not
make sense. Cross-overs are not expected in this context,
as TAVR is not an option for patients with initiated
surgery. SAVR in patients undergoing TAVR is considered
a potential solution for procedural complications. All
results are also reported for the Intent to Treat Population
(all randomized patients). Echocardiogram data will be
analyzed in the Valve Implant population (the subset of
the As Treated population who receive and retain the
intended valve during the index procedure). Sensitivity
analyses will be performed using the Intent to Treat
population (all randomized patients). Time-dependent
variables will be analyzed using the Kaplan-Meier
algorithm, with the log-rank statistic used for group
comparisons.
The primary composite clinical endpoint will be
evaluated in a non-inferiority analysis with a non-
Table II. Schedule of assessments for the RHEIA trial
Procedure Screening Post
procedure
Dischargea 30
days
6
months
12
months
Clinical Assessments
Medical History X
CCS Angina; SYNTAX Score X
NYHA Classification X X X X X
Risk Scores X
Mini-Mental State Examination-2 X X X
NIHSSb; Modified Rankin Scaleb X X X X X X
Frailty Indexc X X X
Non-Invasive Tests
Pulmonary function test Xe
Electrocardiogram X X X X X
Echocardiogram (TTE) Xd X X X
Invasive Procedures
3D Cardiac imaging (CT, TEE, or cardiac MRI)f; CT angiography; Cardiac
catheterization
X
Quality-of-Life
KCCQ and SF-12 X X X
CT, computed tomography; KCCQ, Kansas City Cardiomyopathy Questionnaire; MRI, magnetic resonance imaging; NIHSS, National Institutes of Health Stroke Scale; NYHA, New
York Heart Association; RHEIA, Randomized researcH in womEn all comers wIth Aortic stenosis; SF-12, 12-item Short Form survey; TEE, transesophageal echocardiogram; TTE,
transthoracic echocardiogram.
a For patients discharged b48 hours after exiting the catheter laboratory/operation room, it is not required to repeat tests collected during the post-procedure period that are also
required for the discharge visit.
b Patients diagnosed with stroke after the procedure should undergo a follow-up modified Rankin Scale assessment 90 days after the diagnosis. NIHSS not performed at 6 month.
c Frailty Index includes activities of daily living (ADLs), 5-meter walk test (5MWT), grip strength, and albumin level.
dQualifying echocardiogram must have been performed b90 days prior to randomization.
eOnly for patients with a history of lung disease.
fQualifying imaging must have been performed within 1 year of randomization.
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clinically meaningful based on the recent PARTNER 3
and Evolut LR data, which also used a 6% on-
inferiority margin.18 ,19 The test will be performed
as a one-sided test at alpha = 0.05. Non-inferiority will
be declared if the upper 95% confidence limit for the
difference in event rate between the groups (TAVR –
SAVR) is below 0.06. If the primary endpoint passes
the non-inferiority test, an analysis for superiority will
be performed.
Summary statistics will be produced, including means,
standard deviations, medians and quartiles for continuous
variables, and counts and percentages for categorical
variables. Confidence limits will be computed. Group
comparisons will be performed using t-tests or analysis of
variance (and where appropriate the Wilcoxon rank-sum
test) for continuous variables and Fisher's exact test for
categorical variables. Time-dependent variables will be
analyzed using the Kaplan-Meier algorithm, with the log-
rank statistic used for group comparisons. Adverse events
will be tabulated for 30 days, 6 months and 1 year,
including event counts, patients with events and Kaplan-
Meier event rates at specific time-points, and groups will
be compared using the log-rank test. Unless specified
otherwise, confidence limits and hypothesis tests will be
two-sided, using alpha = 0.05. Analyses will be conduct-
ed using SAS version 9.3 or later (SAS Institute, Cary,
North Carolina, USA).Discussion
The RHEIA study has been designed to evaluate the
safety and efficacy of TAVR compared with SAVR
specifically in women with severe symptomatic aortic
stenosis, irrespective of their level of surgical risk.
Justification for the study
There is evidence of a sex-related difference in
outcomes after SAVR5-8 as well as after TAVR.9-13 In the
WIN TAVI registry the VARC-2 composite safety endpoint
was 16.5% at 1 year with a low incidence of early
mortality and stroke.14 Data from meta-analyses suggest
improved survival in women versus men after TAVR.9-13
Moreover, data from two meta-analyses have indicated
that TAVR may provide a survival benefit compared with
SAVR in women, whereas similar outcomes have been
observed with either intervention among men.16,17 To
date, most data are derived from subgroup analyses of
large trials, and randomized trials comparing outcomes
after TAVR or SAVR specifically in women are lacking.
Moreover, most trials involved patients at intermediate to
high surgical risk, whereas there is increasing evidence
that TAVR may also be suitable for low-risk patients.3,4
Recent randomized trials in low-surgical risk populations,
i.e. PARTNER 3 and EVOLUT Low Risk, demonstrated
non-inferiority or superiority of TAVR vs. SAVR,18,19 but
women were under-represented in these trials.
Figure 2
Sample size considerations.
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evaluating whether there is a difference in clinical
outcomes between TAVR and SAVR in a randomized
trial involving women only, and by including patients
with any level of surgical risk. The study will use SAPIEN 3
valves for TAVR procedures. The PARTNER I, II, and III
trials demonstrated the efficacy and safety of TAVR
performed using SAPIEN heart valves in patients at high,
intermediate and low surgical risk, respectively.18,20,21
With respect to gender differences, late mortality was
reduced in women compared with men in PARTNER I,22
but no sex-specific differences in survival were seen in
PARTNER II.23 There was also no significant sex-specific
difference in the primary endpoint in PARTNER III (a
composite of death, stroke or re-hospitalization at 1 year),
although the rate difference was greater in women
(endpoint rates: TAVR 8.1% versus SAVR 18.5%; differ-
ence −10.4%, 95% CI −18.3 to −2.5) than in men (8.7%
versus 13.8%; difference− 5.1%, 95% CI −9.9 to −0.3).18
Study design and organization
The RHEIA study is a prospective, multicenter, random-
ized, controlled trial. It is designed to determine whether
TAVR is non-inferior, or potentially superior, compared to
SAVR, with respect to safety and efficacy in the treatment ofwomen with severe symptomatic aortic stenosis. Data will
be collected from a range of hospitals in Europe. The
multinational nature of the study increases the applicability
of the study findings to clinical practice across Europe. The
study sites and investigators have been selected to ensure
that thepersonnel and their institutions are suitably qualified,
experienced and equipped to undertake the planned
interventions. The trial management structure has been
designed to provide disciplined oversight of trial activities.
Patient eligibility will be confirmed by a Case Review Board,
echocardiograms will be analyzed by a central imaging
laboratory, and endpoint eventswill be adjudicated by a non-
blinded clinical events committee. A Data Safety Monitoring
Board will review adverse events and maintain oversight of
safety.
The same TAVR systems (SAPIEN 3 or SAPIEN 3 Ultra,
with the Commander Delivery System) will be used at all
centers participating in the trial, and transfemoral
delivery will be undertaken in all patients. Uniform
guidance on peri-procedural anticoagulation/antithrom-
botic therapy will be provided to all centers; there are
currently no validated guidelines for this specific study
population and the guidance has been based on a survey
of the literature, with recommendations provided for the
risk categories used in the PARTNER 2 and 3 trials.18,19
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will be tested for non-inferiority of TAVR versus SAVR, and
if non-inferiority is demonstrated, will then be evaluated for
superiority. In addition, several composite endpoints,
individual safety and efficacy endpoints will be analyzed;
this may provide evidence about possible mechanisms/
reasons underlying any difference identified for the
primary endpoint. Another is transcatheter vs surgical
valve function in female patients with small aortic annuli.
There is some primary evidence that transcatheter valves
may have some advantages in terms of lower residual
gradients and higher effective orifice area in the early
postoperative phase.24 The clinical significance of these
findings have not been demonstrated so far.
The interventionalists cannot be blinded because of the
inherent differences between the two interventions
being studied. However, potential bias will be minimized
in several ways. Consecutive enrolment and central
randomization of patients will minimize selection bias.
Endpoint events will be adjudicated by an independent
Clinical Event Committee, which will reduce assessment
bias. Publication of the study design and protocol details
before analysis of the study results will help prevent
reporting bias.
Conclusions
The RHEIA study is a prospective, multicenter,
randomized, controlled trial that will include women
with symptomatic severe aortic stenosis and will be
performed in Europe. Based on a randomized compari-
son, it will evaluate whether there are differences in
outcomes between TAVR and SAVR among women with
symptomatic severe aortic stenosis requiring aortic valve
replacement, irrespective of their surgical risk. The
results of this study may contribute to optimize the
therapeutic management of severe aortic stenosis in
women.
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